-
Product Insights
Thymoma (Thymic Epithelial Tumor) – Drugs In Development, 2023
Global Markets Direct’s, ‘Thymoma (Thymic Epithelial Tumor) - Drugs In Development, 2023’, provides an overview of the Thymoma (Thymic Epithelial Tumor) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thymoma (Thymic Epithelial Tumor), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Lung Adenocarcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Lung Adenocarcinoma - Drugs In Development, 2023’, provides an overview of the Lung Adenocarcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lung Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Drugs In Development, 2023’, provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Recurrent Head And Neck Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Recurrent Head And Neck Squamous Cell Carcinoma Drug Details: IK-175 (KYN-175) was under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Pembrolizumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Metastatic Transitional (Urothelial) Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Metastatic Transitional (Urothelial) Tract Cancer Drug Details: IK-175 (KYN-175) was under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Non-Small Cell Lung Cancer Drug Details: IK-175 (KYN-175) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Ovarian Cancer Drug Details: IK-175 (KYN-175) is under development for the treatment of...